Is ACRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

593 people get ACRX articles and Market Currents by email alert.

Get email alerts on ACRX »

HEADLINES:

AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference

PR Newswire (Thu, 3:20PM)
AcelRx Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8 • 1 Comment
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results

PR Newswire (May 8, 2013)
AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013

PR Newswire (May 3, 2013)
AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting

PR Newswire (May 2, 2013)
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial

PR Newswire (Apr 24, 2013)
Obagi Medical Products Acquired Wednesday, These Biotechs May Be Next
Scott Matusow • Thu, Mar 21 • 45 Comments
AcelRx Pharmaceutical's Potential Billion-Dollar Treatment Under The Radar
Scott Matusow • Tue, Mar 19 • 19 Comments
AcelRx Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results

PR Newswire (Mar 12, 2013)
Small Pharmas With Imminent Catalysts For March 2013
Chemistfrog • Mon, Mar 11 • 5 Comments
AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013

PR Newswire (Mar 7, 2013)
AcelRx Pharmaceuticals' CEO Presents at Cowen and Company 33rd Annual Health Care Conference (Transcript)
Wed, Mar 6 • 1 Comment
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients

PR Newswire (Mar 4, 2013)
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences

PR Newswire (Feb 27, 2013)
AcelRx Pharmaceuticals Provides Clinical Trial Updates

PR Newswire (Feb 19, 2013)
3 Speculative Healthcare Companies With High Levels Of Insider Ownership
Markus Aarnio • Tue, Feb 19 • 1 Comment
AcelRx Appoints Adrian Adams to Board of Directors as Chairman

PR Newswire (Feb 12, 2013)
Small Pharma Watch List: Week Of February 11th, 2013
Chemistfrog • Mon, Feb 11 • 4 Comments
Imminent Catalysts Should Keep Investor Interest Alive For These Pharmaceuticals - Part II
Chemistfrog • Mon, Feb 4 • 9 Comments

To learn more about Seeking Alpha Pro, click here.

AcelRx Pharmaceutical's Potential Billion-Dollar Treatment Under The Radar
Scott Matusow • Tue, Mar 19 • 19 Comments
AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts
Mike Havrilla • Sat, Dec 22, 2012 • 3 Comments
Favorable AcelRx Stock Offering Price May Catalyze The Company's Share Price
Chemistfrog • Fri, Dec 7, 2012 • 3 Comments
ACRX Falls On Financing, Creating Opportunity Ahead Of Phase III Data
PropThink • Thu, Dec 6, 2012
Rally In AcelRx Gets More Intense On Recent Phase III Data
Brian L. Wilson • Tue, Nov 27, 2012 • 1 Comment
4 Reasons To Buy AcelRx Pharmaceuticals
Markus Aarnio • Mon, Jul 30, 2012 • 10 Comments
AcelRx Pharmaceuticals: Next Generation Of Pain Management Technologies
LifeSci Advisors • Mon, Jul 16, 2012 • 7 Comments
AcelRx Pharma: Pain Drug Developer With 2H12 Phase 3 Catalysts
Mike Havrilla • Wed, Jul 4, 2012 • 1 Comment
AcelRX IPO Prices Well Below Expected Range
SA Editor Mohit Manghnani • Sun, Feb 13, 2011

Obagi Medical Products Acquired Wednesday, These Biotechs May Be Next
Scott Matusow • Thu, Mar 21 • 45 Comments
Small Pharmas With Imminent Catalysts For March 2013
Chemistfrog • Mon, Mar 11 • 5 Comments
3 Speculative Healthcare Companies With High Levels Of Insider Ownership
Markus Aarnio • Tue, Feb 19 • 1 Comment
Small Pharma Watch List: Week Of February 11th, 2013
Chemistfrog • Mon, Feb 11 • 4 Comments
Imminent Catalysts Should Keep Investor Interest Alive For These Pharmaceuticals - Part II
Chemistfrog • Mon, Feb 4 • 9 Comments
'Top Of The Class' Small Pharma Investments For 2013
Chemistfrog • Mon, Jan 14 • 25 Comments
3 Small Pharma Companies With Major Catalysts In 2013
Chemistfrog • Mon, Dec 17, 2012 • 6 Comments
Small Pharmaceuticals With Near Term Catalysts Offer Investment Opportunities
Chemistfrog • Tue, Dec 4, 2012 • 12 Comments
Biotech Weekend Recap: Frustration And Disasters
Brian L. Wilson • Sun, Nov 18, 2012 • 9 Comments
Not-So-Scary Watch List For Week Of Halloween 2012
Chemistfrog • Tue, Oct 30, 2012 • 8 Comments
2 Biotech Companies Investors Should Watch As Analysts Initiate Buy Ratings
Matt Schilling • Sun, Oct 14, 2012 • 2 Comments
Halloween-Like Fears Influence Small Pharma Trading Techniques For 4Q 2012
Chemistfrog • Tue, Oct 9, 2012 • 3 Comments
5 Pharmaceutical Companies To Present At The Rodman And Renshaw Conference On September 11
Markus Aarnio • Mon, Sep 10, 2012 • 6 Comments
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts This Year - Part II
Markus Aarnio • Mon, Aug 13, 2012 • 6 Comments
$1,000,000 Worth Of Insider Buys Last Week
Gutone • Tue, Jun 5, 2012 • 1 Comment
New IPO Filings And What's On The Horizon
IPO Candy • Fri, Feb 3, 2012
Biotech IPO Class of 2011 Takes Drubbing
The Burrill Report • Sun, Aug 14, 2011
IPO Market Slow But Still Healthy
IPO Candy • Thu, Jun 2, 2011
IPO Roundup: What's Candy and What's Bubble Gum
IPO Candy • Wed, May 4, 2011 • 4 Comments
Biotech IPOs Flow: Four Life Sciences Companies Make Their Debut
The Burrill Report • Sun, Feb 13, 2011

AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference

PR Newswire (Thu, 3:20PM)
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results

PR Newswire (May 8, 2013)
AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013

PR Newswire (May 3, 2013)
AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting

PR Newswire (May 2, 2013)
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial

PR Newswire (Apr 24, 2013)
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results

PR Newswire (Mar 12, 2013)
AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013

PR Newswire (Mar 7, 2013)
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients

PR Newswire (Mar 4, 2013)
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences

PR Newswire (Feb 27, 2013)
AcelRx Pharmaceuticals Provides Clinical Trial Updates

PR Newswire (Feb 19, 2013)
AcelRx Appoints Adrian Adams to Board of Directors as Chairman

PR Newswire (Feb 12, 2013)
AcelRx Pharmaceuticals Announces Exercise of Option to Purchase Additional Shares

PR Newswire (Dec 14, 2012)
AcelRx to Present Top-Line Data from Phase 3 Study of Sufentanil NanoTab® PCA System vs. IV PCA Morphine at the 66th Annual PostGraduate Assembly in Anesthesiology held in New York City

PR Newswire (Dec 14, 2012)
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

PR Newswire (Dec 6, 2012)
AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock

PR Newswire (Dec 5, 2012)
AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference

PR Newswire (Nov 20, 2012)
AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain

PR Newswire (Nov 15, 2012)
AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results

PR Newswire (Nov 14, 2012)
AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results

PR Newswire (Nov 6, 2012)
AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study

PR Newswire (Nov 5, 2012)

ACRX vs. ETF Alternatives

Company Description

Currently, there's no company description for ACRX.

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 6:33 PM AcelRx (ACRX): Q1 EPS of -$0.34 misses by $0.07. Revenue of $940K beats by $110K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 24, 8:30 AM AcelRx (ACRX) jumps 3.25% premarket (on top of +4.4% Tuesday) after saying a Phase 2 study of sublingual sufentanil (ARX-04) met its primary endpoint as patients had "significantly greater pain reduction as measured by Summed Pain Intensity Difference to baseline." Context: The idea is to determine an effective, physician-administered dose that can be given less frequently than ARX-01 which is patient-delivered. Jefferies says ARX-01 can reach $400M in sales with little threat from generics. Comment! [Healthcare, On the Move]
Monday, April 8, 10:51 AM AcelRx Pharmaceuticals (ACRX +3.6%) gets a lift after Jefferies initiates the shares with a Buy rating and an $8 price target this morning. Jefferies says it expects FDA approval in 2014 for ACRX's lead product candidate ARX-01, a drug for post-op pain control, in 2014 given the solid body of data from recent tests. The firm notes that the current standard of care for post-op pain control poses hefty barriers to entry, and it is projecting around $400M in peak potential for ARX-01 with minimal threat from generics. Comment! [Healthcare, On the Move]
Tuesday, March 12, 4:42 PM AcelRx (ACRX): Q4 EPS of -$0.41 misses by $0.01. Recognized revenue of $1.7M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 5, 9:34 AM AcelRx Pharmaceuticals (ACRX) jumps 12.45% after saying yesterday that its Sufentanil NanoTab drug-device combination met the primary endpoint of a Phase III trial by significantly reducing pain in patients who had just received major open abdominal surgery. AcelRx expects to release the results of another Phase III trial of NanoTab in Q2. (PR) Comment! [Healthcare, On the Move]
Tuesday, March 5, 9:10 AM Premarket gainers: HIMX +21%. ASNA +13%. ACRX +12%. MTG +11%. SNTS +9%. CREE +6%.
Losers: IPXL -21%. RNIN -16%. Comment! [On the Move]
Friday, December 7, 2012, 9:10 AM Premarket gainers: GALE +9%. ACRX +7%.
Losers: AMRN -19%. ABMD -7%. QRE -5%. Comment! [On the Move]
Wednesday, December 5, 2012, 12:42 PM AcelRx Pharmaceuticals (ACRX -5.3%) slides after announcing a proposed 10M share secondary offering. All of the shares in the offering are to be sold by ACRX. Jefferies and Cowen are acting as joint book-running managers, with Canaccord Genuity acting as co-lead manager. Comment! [Healthcare, On the Move]
Monday, November 26, 2012, 12:45 PM Midday top 10 gainers: CBAK +80%. ENMD +23%. ANAD +19%. SSE +17%. HOGS +16%. SBLK +15%. CLSN +14%. SOMX +15%. GALT +14%. ACRX +12%. Midday top 10 Losers: SAB -14%. MMR -13%. CNIT -12%. CCCL -14%. BZ -9%. ZLC -9%. OXF -8%. MEIP -8%. PSTR -8%. AXX -7%. Comment!
Wednesday, November 21, 2012, 9:10 AM Premarket gainers: MEMS +86%. VELT +10%. SQNM +6%. MIPS +5%. CRUS +5%.
Losers: STV -43%. SCHL -23%. TLYS -15%. ACRX -10%. EBR -10%. Comment! [On the Move]
Thursday, November 15, 2012, 12:45 PM Midday top 10 gainers: RCON +91%. BXG +55%. CALI +45%. SGOC +44%. BGMD +22%. MEET +21%. ACRX +15%. SZYM +13%. DANG +12%. SGYP +11%. Midday top 10 Losers: TZYM -75%. FFEX -48%. TRIT -38%. ATEA -35%. SB -34%. VELT -34%. NAII -25%. OSIS -24%. UTSI -23%. DMND -22%. 1 Comment [On the Move]
Thursday, November 15, 2012, 9:10 AM Premarket gainers: BXG +68%. ACRX +31%. DANG +14%. NTAP +12%. ELOQ +12%. AMRN +7%. LPH +7%.
Losers: VELT -27%. DMND -23%. APPY -17%. TDG -6%. AKS -5%. DRYS -5%. VGR -5%. NGLS -5%. Comment! [On the Move]
Thursday, November 15, 2012, 9:02 AM AcelRx Pharma (ACRX) surges 25% after saying that its under-the-tongue NanoTab system for relieving pain after surgery came out on top in a direct head-to-head with morphine in a Phase III trial. Patients loved it and so did nurses. NanoTab system is being tested in two other late-stage studies. (PR) 1 Comment [On the Move, Healthcare]
Tuesday, January 31, 2012, 11:55 AM AcelRx Pharmaceuticals (ACRX +28.8%) skyrockets after stating it's making progress towards meeting the FDA's software verification and validation requirements for the initiation of Phase 3 trials for its ARX-01 analgesia device, and that patient dosing should begin in late Q1 or early Q2. Comment! [Healthcare, On the Move]

Chemistfrog
$ACRX simply looks "ready" :) Q2 data is imminent...
Apr 20, 7:37 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Fincher
$ACRX many say it should reach 5.5 soon, yet I think we will reach 4.5 sooner..lets see, anyone knows what is happening?
Mar 14, 11:15 AM
Reply (1)

• !Report Abuse
View all 1 replies
Fincher: and 4.5 here we go. anyone any idea what is going on?
Mar 14, 4:02 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I bought $ACRX for a trade, My price target opinion is $5.75, over 6 on good volume. Chart @ http://bit.ly/WJKsfV
Mar 6, 11:21 AM
Reply (2)

• !Report Abuse
View all 2 replies
koksiang_darren: would fold be a good entry now?
Mar 12, 11:33 AM
• !Report Abuse
Scott Matusow: if u plan on holding a year or, most def in my opinion
Mar 13, 4:15 PM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Day-Trade setups: $ACRX $ARCP $ASNA $CREE $HIMX $MU $PERI $YHOO http://stks.co/cMQR
Mar 5, 9:30 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chemistfrog
$ACRX looks to be consolidating for the next leg up. Before or after 1Q data release? $DARA with many imminent catalysts
Feb 5, 5:36 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
Stocks That Insiders Are Buying and Selling February 2011 ++ http://t.co/vwCffa7 ++ $CACB $AN $SGEN $PCRX $ACRX $GEVO $MTSN $BGMD $ZIOP $AOL
2/28/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Fincher
$ACRX many say it should reach 5.5 soon, yet I think we will reach 4.5 sooner..lets see, anyone knows what is happening?
Mar 14, 11:15 AM
Reply (1)

• !Report Abuse
View all 1 replies
Fincher: and 4.5 here we go. anyone any idea what is going on?
Mar 14, 4:02 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I bought $ACRX for a trade, My price target opinion is $5.75, over 6 on good volume. Chart @ http://bit.ly/WJKsfV
Mar 6, 11:21 AM
Reply (2)

• !Report Abuse
View all 2 replies
koksiang_darren: would fold be a good entry now?
Mar 12, 11:33 AM
• !Report Abuse
Scott Matusow: if u plan on holding a year or, most def in my opinion
Mar 13, 4:15 PM
• !Report Abuse
Add a reply...

140 characters

ACRX AcelRx Pharmaceuticals, Inc.

ACRX

AcelRx Pharmaceuticals, Inc.